Definitions
Recurrent pregnancy loss (RPL) -aka recurrent spontaneous abortion (RSA) (or miscarriage) -refers to the occurrence of three or more losses of consecutive pregnancies prior to the 20th week of gestation (excluding ectopic, molar or biochemical pregnancies). The loss may be primary (in women has never carried to viability) or secondary (after a previous live birth). Causative factors include anatomic, chromosomal, hormonal or immunological abnormalities, as well as thrombolytic disorders, or underlying factors of unknown etiology.
Guideline
Members are eligible for coverage of the evaluation and treatment of RPL (≥ 2 lost spontaneous miscarriages in < 20 weeks) per the table below. 1. Angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms testing 2. Antibodies to phosphatidylserine, phosphatidylethanolamine or phospholipids (except anticardiolipin and lupus anticoagulant, as depicted in table above) 3. Cytokine polymorphisms analysis (Th1/Th2 intra-cellular cytokine ratio) 4. Natural killer (NK) testing to determinat circulating-cell % or status of NK-like cells through luteal phase biopsy 5. Embryo toxicity assay (ETA) 6. Genetic association studies of inflammatory cytokine polymorphisms 7. Inter-α trypsin inhibitor-heavy chain 4 (ITI-H4) (as a biomarker for recurrent pregnancy loss) 8. Maternal antiparental antibodies 9. Methylenetetrahydrofolate reductase (MTHFR) testing 10. Molecular cytogenetic testing (serological or on products of conception) using comparative genomic hybridization (CGH) 11. Molecular genetic testing for highly skewed X-inactivation patterns 12. Parental human leukocyte antigen (HLA) status 13. Pre-implantation genetic screening (PGS) (See Assisted Reproductive Technologies [ART] to determine whether members pursuing ART services meet PGS criteria) 14. Reproductive immunophenotype (CD3+, CD4+, CD5+, CD8+, CD16+, CD19+, CD56+) 15. Routine preimplantation embryo aneuploidy screening 16. Tests for embryotoxic factor 17. Tests for inherited thrombophilic disorders: factor V Leiden (genetic testing), prothrombin G20210A mutation, serum homocysteine, and deficiencies of the anticoagulants protein C, protein S, and antithrombin II 18. Tests for maternal antileukocytic antibodies to paternal leukocytes 19. Tests for serum "blocking factor" 20. X-chromosome inactivation study 
